Clinical Trial Goal
To find out:
- The highest dose of BI-1808 that's safe to give
- If BI-1808, alone and in combination with pembrolizumab, is safe and works well to CTCL
You may be able to join this trial if you:
- Are 18 years old or older
- Have CTCL. Some examples include:
- Mycosis fungoides
- Sezary syndrome
- Do not have lymphoma in your brain or spinal cord
- Do not have graft-versus-host-disease (GVHD)
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
BI-1808 is a human IgG1 monoclonal antibody that targets TNFR2 on certain cells.
Pembrolizumab is a checkpoint inhibitor that targets PD-1 on certain cells.
You’ll get:
Pembrolizumab is a checkpoint inhibitor that targets PD-1 on certain cells.
You’ll get:
- BI-1808 – Given as intravenous (IV) infusions 1 time every 3 weeks
- Pembrolizumab – Given as IV infusions 1 time every 3 weeks
You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 2 years.
The Food and Drug Administration (FDA) has not yet approved BI-1808.
Contacts
Susanne Gertsson, +46462868550, susanne.gertsson@bioinvent.com
Mona Welschof, PhD, +47 97088721, mona.welschof@bioinvent.com
Locations
City of Hope National Medical CenterRECRUITING
Duarte, California
Christiane Querfeld
University of PennsylvaniaRECRUITING
Philadelphia, Pennsylvania
Stefan Barta
Sponsors
lead: BioInvent International AB, collaborator: Merck Sharp & Dohme LLC
